New drug combo shows promise for Hard-to-Treat cervical cancer
NCT ID NCT04651127
First seen Mar 27, 2026 · Last updated May 15, 2026 · Updated 8 times
Summary
This study tested a combination of two drugs, toripalimab (an immunotherapy) and chidamide (a targeted therapy), in women with advanced cervical cancer that had returned or spread. The goal was to see if the combination was safe and could shrink tumors. Only 5 women took part before the study was stopped early. The approach aims to control the disease, not cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Centre
Guangzhou, Guangdong, 510060, China
Conditions
Explore the condition pages connected to this study.